Skip to main content
Vor Biopharma Inc. logo

Vor Biopharma Inc. — Investor Relations & Filings

Ticker · VOR ISIN · US9290331084 US Professional, scientific and technical activities
Open in API
Filings indexed 406 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US VOR

About Vor Biopharma Inc.

https://www.vorbio.com/

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing treatments for autoimmune diseases. The company is committed to advancing medicines that target the fundamental drivers of autoimmunity, aiming to move beyond symptom control. Its lead candidate, telitacicept, is designed to silence the signals that allow harmful immune cells to survive. The company's objective is to deliver safer, longer-lasting therapies that address the source of autoimmune conditions.

Recent filings

Filing Released Lang Actions
10-Q - Vor Biopharma Inc. (0001817229) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
ARS - Vor Biopharma Inc. (0001817229) (Filer)
Annual Report
2026-04-27 English
DEF 14A - Vor Biopharma Inc. (0001817229) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English
S-8 - Vor Biopharma Inc. (0001817229) (Filer)
Capital/Financing Update Classification · 95% confidence The document is an Exhibit 107 filing fee calculation table related to Form S-8 for Vor Biopharma Inc. It details the registration fee calculation for securities under equity incentive and employee stock purchase plans. There are no financial statements, management discussion, or earnings data. The content is specific to registration fees for securities offerings under the Securities Act, which is typical for capital raising or securities registration filings. This aligns with a Capital/Financing Update (CAP) filing type, as it relates to registration of securities for issuance under employee plans and the associated fees. The document is not an annual report, earnings release, or any other report type but a regulatory filing related to capital structure changes and securities registration.
2026-03-30 English
10-K - Vor Biopharma Inc. (0001817229) (Filer)
Annual Report
2026-03-30 English
8-K - Vor Biopharma Inc. (0001817229) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a private placement financing transaction where the company agreed to issue shares to investors, including details about the securities purchase agreement and registration rights agreement. There are no financial statements or detailed financial performance data included, only disclosures about the financing event and related agreements. This fits the definition of a Capital/Financing Update, as it provides updates on company fundraising and capital structure changes. The document length is over 10,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-03-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.